ReviewClinical and translational medicine2017
Using single-cell multiple omics approaches to resolve tumor heterogeneity.
Review in Clinical and translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Basement membrane related genes in lung adenocarcinoma prognostic risk model based on single cell and bulk RNA sequencing and tumor microenvironment modulation.Discover oncology · 2026Article
- Single-cell identifies and validates human circulating Treg subtype/state TregSignal transduction and targeted therapy · 2026Article
- Integrative Sequencing and Proteogenomic Approaches to Intratumoral Heterogeneity in Cholangiocarcinoma: Implications for Precision Diagnosis and Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.Molecular therapy. Oncology · 2024Article
- Serial single-cell RNA sequencing unveils drug resistance and metastatic traits in stage IV breast cancer.NPJ precision oncology · 2024Article
- TCfinder: Robust tumor cell discrimination in scRNA-seq based on gene pathway activity.iMetaOmics · 2024Article
- Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.Cancer research · 2024Article
- Resolving tumor evolution: a phylogenetic approach.Journal of the National Cancer Center · 2024Review
- An update review of the application of single-cell RNA sequencing in pregnancy-related diseases.Frontiers in endocrinology · 2024Review
- Establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line: RsNF.Human cell · 2024Article
- Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine.Frontiers in physiology · 2024Review
- Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles.bioRxiv : the preprint server for biology · 2023Article
- ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs.Nature communications · 2023Article
- Computational single cell oncology: state of the art.Frontiers in genetics · 2023Review
- Evaluation of pulmonary single-cell identity specificity in scRNA-seq analysis.Clinical and translational medicine · 2022Article
- Functional stratification of cancer drugs through integrated network similarity.NPJ systems biology and applications · 2022Article
- Forward single-cell sequencing into clinical application: Understanding of cancer microenvironment at single-cell solution.Clinical and translational medicine · 2022Article
- Review
- Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.Frontiers in genetics · 2022Article
- Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures.BioMed research international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
It has become increasingly clear that both normal and cancer tissues are composed of heterogeneous populations. Genetic variation can be attributed to the downstream effects of inherited mutations, environmental factors, or inaccurately resolved errors in transcription and replication. When lesions occur in regions that confer a proliferative advantage, it can support clonal expansion, subclonal variation, and neoplastic progression. In this manner, the complex heterogeneous microenvironment of a tumour promotes the likelihood of angiogenesis and metastasis. Recent advances in next-generation sequencing and computational biology have utilized single-cell applications to build deep profiles of individual cells that are otherwise masked in bulk profiling. In addition, the development of new techniques for combining single-cell multi-omic strategies is providing a more precise understanding of factors contributing to cellular identity, function, and growth. Continuing advancements in single-cell technology and computational deconvolution of data will be critical for reconstructing patient specific intra-tumour features and developing more personalized cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.